VSAM
NTLA icon

Value Star Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Value Star Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-20,700
Closed -$655K – 24
2023
Q3 		$655K Hold
20,700
– – 0.23% 22
2023
Q2 		$844K Buy
20,700
+5,950
+40% +$241K 0.25% 27
2023
Q1 		$550K Buy
+14,750
New +$578K 0.22% 23

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Value Star Asset Management's NTLA Position: Q4 2023 in Review

Value Star Asset Management sold out of Intellia Therapeutics (NTLA) in Q4 2023, closing a stake of 20,700 shares — an estimated $655K sold.

Value Star Asset Management first reported a position in NTLA in Q1 2023 and held it in 3 quarters. The position peaked at $844K in Q2 2023. 292 funds tracked by Wall St. Rank hold NTLA as of Q4 2023.

  • Value Star Asset Management reported no remaining Intellia Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Value Star Asset Management sold 20,700 Intellia Therapeutics shares in Q4 2023, an estimated $655K.
  • Value Star Asset Management first reported a position in Intellia Therapeutics in Q1 2023 and held it in 3 quarters.
  • Value Star Asset Management's Intellia Therapeutics position peaked at $844K in Q2 2023.
  • 292 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2023.

Based on Value Star Asset Management's 13F filing for Q4 2023, filed 6 Feb 2024.